Compare Dropbox Inc (DBX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Sana Biotechnology Inc — how do they compare? Dropbox Inc trades at $34.36 (market cap $7.42B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Dropbox Inc is far larger — about 8.9× Sana Biotechnology Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Sana Biotechnology Inc for 23 Days on average.
| DBX | SANA | |
|---|---|---|
Market Cap | $7.42B | $836.71M |
Volume | 3,061,580 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $37.74 | $5.92 |
52-Week Low | $22.06 | $2.68 |
Typical Hold Time | 97 Days | 23 Days |
Enterprise Value | $10.29B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBX trades at $34.14, up 3.2% today, with a bullish technical signal and consistent earnings beats. Revenue is stable around $2.5B annually, with a strong net income margin of 17.49% in 2025. Recent news highlights insider selling and a security breach affecting 5,000 accounts (Reuters, 2026-09-01).
Outlook is mixed: solid profitability and cash flow support valuation, but high debt and insider sales pose risks. Analyst consensus is divided, with a $26.83 price target below current levels, suggesting caution amid growth concerns.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
